Registration Links (4 Options)
Speakers Reg Patient Reg Reg for Clinical Trials Community Network
Logo

Molecular Imaging & PET-CT

Principles of positron emission tomography, radiotracer biochemistry, theranostic oncology, and hybrid anatomical-metabolic tumor staging.

Overview

Molecular imaging integrates high-resolution anatomical imaging (Computed Tomography - CT or Magnetic Resonance Imaging - MRI) with metabolic and cellular biomarker mapping using Positron Emission Tomography (PET). By exploiting the increased glucose consumption (Warburg Effect) or specific cell-surface receptor overexpression of neoplastic tissue, PET-CT detects macroscopic and microscopic tumor lesions before structural anatomical alterations become radiographically evident.

Major Oncological Radiotracers

Radiotracer Target / Mechanism Clinical Malignancies Clinical Role
18F-Fluorodeoxyglucose (18F-FDG) Glucose analog trapped intracellularly via hexokinase phosphorylation. Lymphomas, Non-Small Cell Lung Cancer, Colorectal, Esophageal, Melanoma Primary staging, restaging, therapy response evaluation (PERCIST criteria), recurrence detection
68Ga / 18F-PSMA (PSMA-11, DCFPyL) Prostate-Specific Membrane Antigen transmembrane glycoprotein binding. Prostate Adenocarcinoma Initial high-risk staging, biochemical recurrence localization at PSA levels <0.5 ng/mL
68Ga-DOTATATE / DOTATOC Somatostatin Receptor (SSTR-2) peptide agonist targeting. Neuroendocrine Tumors (NETs), Carcinoid, Pheochromocytoma SSTR staging, peptide receptor radionuclide therapy (PRRT) eligibility screening
18F-Fluoroestradiol (18F-FES) Estrogen Receptor (ER) binding assessment. ER-Positive Metastatic Breast Cancer Evaluating whole-body ER expression heterogeneity and endocrine therapy response

Clinical Indications Across the Cancer Continuum

  • Initial Staging & TNM Classification: Accurately characterizes occult distant metastases and mediastinal/retroperitoneal lymphadenopathy, preventing unnecessary non-curative surgical procedures.
  • Therapeutic Response Assessment: Differentiates active residual tumor tissue from non-viable treatment-induced necrosis or post-radiation fibrosis.
  • Radiotherapy Treatment Planning: Fusing PET-CT with simulation scans to delineate biological target volumes (BTV) for dose escalation.
  • Biopsy Target Localization: Pinpoints hypermetabolic tumor areas to avoid non-diagnostic sampling of central necrotic cores.

Theranostics: Connecting Diagnostics to Targeted Radioligand Therapy

Theranostics pairs a diagnostic imaging radiotracer with a therapeutic beta- or alpha-emitting radioisotope utilizing identical cellular receptors:

  • Prostate Cancer: Diagnostic 68Ga-PSMA-11 imaging paired with therapeutic 177Lu-PSMA-617 (Pluvicto) radioligand therapy.
  • Neuroendocrine Tumors: Diagnostic 68Ga-DOTATATE paired with therapeutic 177Lu-DOTATATE (Lutathera) peptide receptor radionuclide therapy.
Molecular imaging scans require careful patient preparation, including pre-scan fasting for 18F-FDG to normalize blood glucose levels, ensuring optimal image quality and accurate quantitative SUV calculation.